We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 28 Sep 2021

Randox Laboratories (Crumlin, UK) showcased its pioneering diagnostic technologies at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, which saw breakthrough innovations shaping the future of clinical testing and patient care. More...

With more than 400 companies exhibiting, the 2021 AACC Clinical Lab Expo is the premier global laboratory medicine exposition. Among its diverse product range displayed at AACC 2021 were third party quality control solutions, diagnostic reagents which included many niche & superior performance assays, clinical chemistry analyzers, molecular diagnostic solutions for infectious diseases including COVID-19 and patented biochip technology. The revolutionary biochip is capable of simultaneously detecting hundreds of targets from a single patient sample. Complete patient profiling in this way facilitates faster patient testing, earlier diagnosis and improved patient pathways.

Randox also demonstrated its Qnostics range of molecular controls for infectious diseases comprising hundreds of characterized viral, bacterial and fungal targets covering a wide range of diseases and infections. Comprising hundreds of characterized viral, bacterial and fungal targets, the Qnostics range includes transplant associated diseases, respiratory diseases, blood borne viruses, sexually transmitted infections, gastrointestinal infections and central nervous system diseases. The products can be used in the daily monitoring of assay performance, linearity assessment, assay evaluation, validation and verification of new assays and staff training.

Also on display at the event were the company’s Acusera Anti-SARS-CoV-2 controls which support assay validation and routine performance monitoring of serological assays for COVID-19. Conveniently supplied in a liquid format, this control has unrivalled 30-day open vial stability, therefore keeping waste to a minimum.

Related Links:
Randox Laboratories


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.